Filing Details

Accession Number:
0001209191-21-011010
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-16 19:43:50
Reporting Period:
2021-02-11
Accepted Time:
2021-02-16 19:43:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI Biological Products, (No Disgnostic Substances) (2836) 463872213
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724605 Carole Ho C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-11 2,756 $70.17 172,633 No 4 S Indirect See footnote
Common Stock Disposition 2021-02-11 400 $71.49 172,233 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 25,000 Indirect See footnote
Common Stock 82,382 Direct
Footnotes
  1. Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.79 to $70.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. Includes 7,468 shares acquired pursuant to vesting of restricted stock units and issued directly to the Rohatgi-Ho Family 2009 Revocable Trust.
  4. The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
  5. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.01 to $71.705 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  6. The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust, for which the Reporting Person serves as trustee.
  7. The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 80,906 previously reported restricted stock units.